Harold E. Bays
L-MARC Research Center
Louisville
Kentucky 40213
USA
Name/email consistency: medium
- Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity. Bays, H.E., Gadde, K.M. Drugs. Today (2011)
- Colesevelam hydrochloride added to background metformin therapy in patients with type 2 diabetes mellitus: a pooled analysis from 3 clinical studies. Bays, H.E. Endocr. Pract (2011)
- MBX-8025, A Novel Peroxisome Proliferator Receptor-{delta} Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin. Bays, H.E., Schwartz, S., Littlejohn, T., Kerzner, B., Krauss, R.M., Karpf, D.B., Choi, Y.J., Wang, X., Naim, S., Roberts, B.K. J. Clin. Endocrinol. Metab. (2011)
- Effects of coadministered ezetimibe plus fenofibrate in mixed dyslipidemic patients with metabolic syndrome. Bays, H.E., Shah, A., Macdonell, G., Taggart, W.V., Gumbiner, B. Metab. Syndr. Relat. Disord (2011)
- Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development. Bays, H.E. Expert. Rev. Cardiovasc. Ther (2011)
- Colesevelam hydrochloride powder for oral suspension versus cholestyramine powder for oral suspension: comparison of acceptability and tolerability. Bays, H.E., Maki, K.C., Schmitz, K. Endocr. Pract (2011)
- Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. Bays, H., Shah, A., Dong, Q., McCrary Sisk, C., Maccubbin, D. Int. J. Clin. Pract. (2011)
- Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. Bays, H.E., Shah, A., Lin, J., McCrary Sisk, C., Paolini, J.F., Maccubbin, D. J. Clin. Lipidol (2010)
- The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia. Bays, H.E., Roth, E.M., McKenney, J.M., Kelly, M.T., Thakker, K.M., Setze, C.M., Obermeyer, K., Sleep, D.J. Diabetes. Care (2010)
- Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients. Bays, H.E., Maki, K.C., McKenney, J., Snipes, R., Meadowcroft, A., Schroyer, R., Doyle, R.T., Stein, E. Curr. Med. Res. Opin (2010)
- Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin. Bays, H.E., McKenney, J., Maki, K.C., Doyle, R.T., Carter, R.N., Stein, E. Mayo Clin. Proc. (2010)
- Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading? Bays, H., Conard, S., Leiter, L.A., Bird, S., Jensen, E., Hanson, M.E., Shah, A., Tershakovec, A.M. Lipids. Health. Dis (2010)
- Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease. Bays, H. Expert. Rev. Cardiovasc. Ther (2010)
- From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Bays, H. Curr. Med. Res. Opin (2009)
- The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels. Bays, H.E., Maki, K.C., Doyle, R.T., Stein, E. Postgrad. Med (2009)
- Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease. Bays, H.E. Expert. Rev. Cardiovasc. Ther (2009)
- What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush? Bays, H.E., Ballantyne, C. Curr. Opin. Lipidol. (2009)
- Does nicotinic acid (niacin) lower blood pressure? Bays, H.E., Rader, D.J. Int. J. Clin. Pract. (2009)
- Adiposopathy and bariatric surgery: is 'sick fat' a surgical disease? Bays, H.E., Laferrère, B., Dixon, J., Aronne, L., González-Campoy, J.M., Apovian, C., Wolfe, B.M. Int. J. Clin. Pract. (2009)
- "Sick fat," metabolic disease, and atherosclerosis. Bays, H.E. Am. J. Med. (2009)
- Review of ARBITER 2: extended-release niacin added to statin therapy slows the progression of atherosclerosis. Commentary. Bays, H. Postgrad. Med (2009)
- Perceived body image in men and women with type 2 diabetes mellitus: correlation of body mass index with the figure rating scale. Bays, H.E., Bazata, D.D., Fox, K.M., Grandy, S., Gavin, J.R. Nutr. J (2009)
- Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians. Bays, H. Drugs. Today (2008)
- Safety of niacin and simvastatin combination therapy. Bays, H. Am. J. Cardiol. (2008)
- Is adiposopathy (sick fat) an endocrine disease? Bays, H.E., González-Campoy, J.M., Henry, R.R., Bergman, D.A., Kitabchi, A.E., Schorr, A.B., Rodbard, H.W. Int. J. Clin. Pract. (2008)
- Ezetimibe: cholesterol lowering and beyond. Bays, H.E., Neff, D., Tomassini, J.E., Tershakovec, A.M. Expert. Rev. Cardiovasc. Ther (2008)
- Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia. Bays, H., Sapre, A., Taggart, W., Liu, J., Capece, R., Tershakovec, A. Curr. Med. Res. Opin (2008)
- Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Bays, H.E., Goldberg, R.B., Truitt, K.E., Jones, M.R. Arch. Intern. Med. (2008)
- Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Bays, H.E., Tighe, A.P., Sadovsky, R., Davidson, M.H. Expert. Rev. Cardiovasc. Ther (2008)
- Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Bays, H.E., González-Campoy, J.M., Bray, G.A., Kitabchi, A.E., Bergman, D.A., Schorr, A.B., Rodbard, H.W., Henry, R.R. Expert. Rev. Cardiovasc. Ther (2008)
- Prevalence of self-reported diagnosis of diabetes mellitus and associated risk factors in a national survey in the US population: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes). Bays, H.E., Bazata, D.D., Clark, N.G., Gavin, J.R., Green, A.J., Lewis, S.J., Reed, M.L., Stewart, W., Chapman, R.H., Fox, K.M., Grandy, S. BMC. Public. Health (2007)
- Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk. Bays, H., Rodbard, H.W., Schorr, A.B., González-Campoy, J.M. Curr. Treat. Options. Cardiovasc. Med (2007)
- The 'forgotten' bile acid sequestrants: is now a good time to remember? Bays, H.E., Goldberg, R.B. Am. J. Ther (2007)
- A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus. Bays, H., McElhattan, J., Bryzinski, B.S. Diab. Vasc. Dis. Res (2007)
- Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus. Bays, H.E., Cohen, D.E. Curr. Med. Res. Opin (2007)
- Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors. Bays, H., Jones, P.H. Vasc. Health. Risk. Manag (2007)
- Safety considerations with omega-3 fatty acid therapy. Bays, H.E. Am. J. Cardiol. (2007)
- The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Bays, H.E., Chapman, R.H., Grandy, S. Int. J. Clin. Pract. (2007)
- Adiposopathy is a more rational treatment target for metabolic disease than obesity alone. Bays, H., Dujovne, C.A. Curr. Atheroscler. Rep (2006)
- Statin safety: an overview and assessment of the data--2005. Bays, H. Am. J. Cardiol. (2006)
- Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Bays, H.E., Davidson, M., Jones, M.R., Abby, S.L. Am. J. Cardiol. (2006)
- Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Bays, H. Am. J. Cardiol. (2006)
- The melanocortin system as a therapeutic treatment target for adiposity and adiposopathy. Bays, H. Drugs. R. D (2006)
- Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Bays, H., Rhyne, J., Abby, S., Lai, Y.L., Jones, M. Curr. Med. Res. Opin (2006)
- Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?. Bays, H., Blonde, L., Rosenson, R. Expert. Rev. Cardiovasc. Ther (2006)
- Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything. Bays, H. Expert. Rev. Cardiovasc. Ther (2005)
- Time as a variable with niacin extended-release/lovastatin vs. atorvastatin and simvastatin. Bays, H.E., McGovern, M.E. Prev. Cardiol (2005)
- Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia. Bays, H., Abate, N., Chandalia, M. Future. Cardiol (2005)
- Extended-release niacin/lovastatin: the first combination product for dyslipidemia. Bays, H.E. Expert. Rev. Cardiovasc. Ther (2004)
- Current and investigational antiobesity agents and obesity therapeutic treatment targets. Bays, H.E. Obes. Res. (2004)
- A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Bays, H.E., Ose, L., Fraser, N., Tribble, D.L., Quinto, K., Reyes, R., Johnson-Levonas, A.O., Sapre, A., Donahue, S.R. Clin. Ther (2004)
- Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol. Bays, H.E., McKenney, J.M., Dujovne, C.A., Schrott, H.G., Zema, M.J., Nyberg, J., MacDougall, D.E. Am. J. Cardiol. (2003)
- Pharmacotherapy for dyslipidaemia--current therapies and future agents. Bays, H., Stein, E.A. Expert. Opin. Pharmacother (2003)
